Compare PDC & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | ABP |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 12.5M |
| IPO Year | N/A | N/A |
| Metric | PDC | ABP |
|---|---|---|
| Price | $4.87 | $0.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 221.9K | ★ 4.1M |
| Earning Date | 03-02-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,083,071.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 145.52 | 50.00 |
| 52 Week Low | $1.64 | $0.70 |
| 52 Week High | $10.50 | $34.65 |
| Indicator | PDC | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 19.87 |
| Support Level | $3.85 | $1.44 |
| Resistance Level | $5.70 | $2.89 |
| Average True Range (ATR) | 0.79 | 0.38 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 40.09 | 2.29 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.